Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

http://www.wikidata.org/entity/Q35014817

about

Spontaneous free perforation of the small intestine in adults Crizotinib-induced Rectal Perforation with Abscess.

P2860

Q34008837-3723E453-2F48-4C42-AB0F-7C34FF0EC456 Q47114588-5F5EFE7D-6502-4346-A94D-6465A913CEC1

P2860

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

http://www.wikidata.org/entity/Q35014817

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@ast

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@en

type

label

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@ast

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@en

prefLabel

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@ast

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@en

P1433

Q35014817-836A0DF3-E2E4-46DB-A39A-24B702A04751

P1476

Q35014817-915E147B-6EE9-4AAC-88BC-3C4E092114A7

P2093

Q35014817-1AAAF98B-BD6A-40F3-99E2-64F3C3323523

Q35014817-4DF3FA7B-02BB-4173-91E4-C445218E3F6A

Q35014817-63888763-5105-4CC3-A58B-38F697F640FB

Q35014817-66287F80-4317-4BD3-B6A6-80F695141390

Q35014817-8060F7A0-42FE-4619-94B8-FA9B356F151A

Q35014817-B0A63B76-E969-4CE7-9495-BC4F68C6088B

Q35014817-D5A53BF2-309B-4FBF-B6CC-50602D542410

Q35014817-EC975B9A-26D5-4FD4-9C15-166598FD6E51

Q35014817-F95B53DF-77CE-477A-845B-2B5783FF990A

P2860

Q35014817-20633CC9-B245-4E9E-8E4A-A78A3A059247

Q35014817-38388747-DCBD-4172-93C7-41B6C9E12FA3

Q35014817-4EC23CA5-8C87-4ED4-88D3-331B0330362A

Q35014817-56967593-5767-4BB1-B759-0A074F45558F

Q35014817-603A619B-E9A5-483A-B6CC-FD09136D9692

Q35014817-606DCDB9-B5B3-4F19-B010-A8BDF7345591

Q35014817-7882E548-702B-4BC4-B12D-8464686CFD9C

Q35014817-94A3914F-63C0-4F90-B6F0-88D264953106

Q35014817-B3461B2B-65A8-45BE-8702-F43FBE2648AA

Q35014817-B59875D7-AC85-4F97-9412-E9F823D5A0C1

P304

Q35014817-E71E0389-4590-44DD-8301-978499D01B88

P31

Q35014817-C76C9A8F-3443-4CA5-BDCC-617BD6900362

Q35014817-dcb1403b-f044-4475-919c-afa946004269

P356

Q35014817-EE718914-6FF9-42FC-A572-2D6FF5107EC4

P433

Q35014817-215E87D8-77DF-465E-B4A1-A8865D7C786C

P478

Q35014817-3119B13E-BCA4-43CB-BDD4-D763787C8879

P577

Q35014817-A70DB4EF-5257-4603-92DB-9546C79C8828

P5875

Q35014817-E9944891-EB0B-4967-A6EE-53EC3AB324D8

P698

Q35014817-C80D50BC-2814-47CA-B91B-90A9656FD8A0

P932

Q35014817-52B3E047-E71C-4441-B12A-96B21BD48E4C

P356

YMJ.2011.52.4.695

P1433

Yonsei Medical Journal

P1476

Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

@en

P2093

Cha Young Kim

http://www.w3.org/2001/XMLSchema#string

Dae-Hong Jeon

http://www.w3.org/2001/XMLSchema#string

Gyeong-Won Lee

http://www.w3.org/2001/XMLSchema#string

Hee Jin Kim

http://www.w3.org/2001/XMLSchema#string

Min Gyu Kang

http://www.w3.org/2001/XMLSchema#string

Moon Jin Kim

http://www.w3.org/2001/XMLSchema#string

Sang Su Lee

http://www.w3.org/2001/XMLSchema#string

Yu Eun Kim

http://www.w3.org/2001/XMLSchema#string

Yun-Hong Cheon

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Bevacizumab in non-small cell lung cancer.

Bowel perforation in non-small cell lung cancer after bevacizumab therapy.

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Gastrointestinal perforation due to bevacizumab in colorectal cancer.

P304

695-698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3349/YMJ.2011.52.4.695

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51175751

http://www.w3.org/2001/XMLSchema#string

P698

21623617

http://www.w3.org/2001/XMLSchema#string

P932

3104451

http://www.w3.org/2001/XMLSchema#string